Abstract
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. It is recognized as a systemic disorder, involving airflow limitation, persistent inflammation, oxidative stress, and vascular dysfunction. Pulmonary hypertension (PH) is a clinically relevant and often underdiagnosed complication, impacting prognosis, functional capacity, and survival. Recent evidence shows that PH in COPD can develop early, even in moderate disease, and is associated with pulmonary vascular remodeling, endothelial dysfunction, and systemic inflammation. Distinct phenotypes, including disproportionate PH-COPD forms, exhibit severe hemodynamic impairment and poor outcomes. This review critically synthesizes current literature on the epidemiology, pathophysiology, clinical relevance, and therapeutic strategies for PH-COPD. Emerging complementary approaches targeting oxidative stress, inflammation, and endothelial dysfunction, including medical ozone therapy, are also discussed.

This publication has 7 references indexed in Scilit: